HK1255257A1 - Combination of direct acting antiviral agents and ribavirin for treating hcv patients - Google Patents

Combination of direct acting antiviral agents and ribavirin for treating hcv patients Download PDF

Info

Publication number
HK1255257A1
HK1255257A1 HK18114396.1A HK18114396A HK1255257A1 HK 1255257 A1 HK1255257 A1 HK 1255257A1 HK 18114396 A HK18114396 A HK 18114396A HK 1255257 A1 HK1255257 A1 HK 1255257A1
Authority
HK
Hong Kong
Prior art keywords
compound
patient
daas
weeks
treatment
Prior art date
Application number
HK18114396.1A
Other languages
English (en)
Chinese (zh)
Inventor
M. Bernstein Barry
Dutta Sandeep
Liu Wei
J. Podsadecki Thomas
L. Campbell Andrew
M. Menon Rajeev
Lin Chih-Wei
Wang Tianli
M. Awni Walid
Mensing Sven
Original Assignee
Abbvie Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50771575&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1255257(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc. filed Critical Abbvie Inc.
Publication of HK1255257A1 publication Critical patent/HK1255257A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK18114396.1A 2013-03-14 2018-11-09 Combination of direct acting antiviral agents and ribavirin for treating hcv patients HK1255257A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361783437P 2013-03-14 2013-03-14
US201361783437P 2013-03-14

Publications (1)

Publication Number Publication Date
HK1255257A1 true HK1255257A1 (en) 2019-08-09

Family

ID=50771575

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18114396.1A HK1255257A1 (en) 2013-03-14 2018-11-09 Combination of direct acting antiviral agents and ribavirin for treating hcv patients

Country Status (28)

Country Link
US (1) US20140274934A1 (enExample)
EP (4) EP3318258B1 (enExample)
JP (3) JP6563894B2 (enExample)
KR (2) KR101853605B1 (enExample)
CN (3) CN108187056A (enExample)
AU (3) AU2014239322B2 (enExample)
BR (1) BR112015020918A2 (enExample)
CA (1) CA2901818C (enExample)
CY (1) CY1121474T1 (enExample)
DK (1) DK2968302T3 (enExample)
EA (2) EA201890507A1 (enExample)
ES (1) ES2654109T3 (enExample)
HK (1) HK1255257A1 (enExample)
HR (1) HRP20171898T1 (enExample)
HU (1) HUE036069T2 (enExample)
IL (2) IL240445B (enExample)
LT (1) LT2968302T (enExample)
MX (1) MX2015012536A (enExample)
NO (1) NO3090119T3 (enExample)
PL (1) PL2968302T4 (enExample)
PT (1) PT2968302T (enExample)
RS (1) RS56735B1 (enExample)
SG (2) SG10201709840UA (enExample)
SI (1) SI2968302T1 (enExample)
SM (1) SMT201800017T1 (enExample)
TW (2) TWI678205B (enExample)
WO (1) WO2014152635A1 (enExample)
ZA (1) ZA201705080B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
EA201890507A1 (ru) * 2013-03-14 2018-07-31 Эббви Инк. Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv
JP2016534082A (ja) * 2013-10-25 2016-11-04 アッヴィ・インコーポレイテッド Ｈｃｖの治療方法
US20150174194A1 (en) * 2013-12-19 2015-06-25 Abbvie Inc. Methods for treating liver transplant recipients
JP6559701B2 (ja) * 2014-04-02 2019-08-14 アッヴィ・インコーポレイテッド Ｈｃｖを処置するための方法
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
CN108778764B (zh) 2016-01-08 2020-09-04 恩图鲁斯特咨询卡有限公司 具有卡片返回路径的卡片印刷机构
EP3448392A4 (en) 2016-04-28 2020-01-15 Emory University ALKYNOUS THERAPEUTIC NUCLEOTIDE AND NUCLEOSIDE COMPOSITIONS AND RELATED APPLICATIONS
WO2018057919A1 (en) * 2016-09-23 2018-03-29 Abbvie Inc. Dose adjustment
JP2018131439A (ja) * 2017-02-14 2018-08-23 アッヴィ・インコーポレイテッド Ｈｃｖを処置する方法
CA2981993A1 (en) * 2017-08-02 2019-02-02 Abbvie Inc. Methods for treating hcv
CN108329332A (zh) * 2018-03-16 2018-07-27 安徽华昌高科药业有限公司 一种制备Glecaprevir的方法
KR20200140865A (ko) * 2018-04-10 2020-12-16 아테아 파마슈티컬즈, 인크. 간경변증을 갖는 hcv 감염 환자의 치료

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2010153688A (ru) * 2008-06-10 2012-07-20 Янссен Фармацевтика Нв (Be) Режим дозирования телапревира
US8937150B2 (en) * 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
PE20110679A1 (es) * 2009-06-11 2011-10-20 Abbvie Bahamas Ltd Derivados de (4-tert-butilfenil)pirrolidin-2,5-difenil como inhibidores del hcv
PE20140015A1 (es) * 2010-09-21 2014-02-16 Enanta Pharm Inc Inhibidores de las proteasas de serina del vhc derivados de prolinas macrociclicas
CH707030B1 (de) 2011-10-21 2015-03-13 Abbvie Inc Kombinationsbehandlung von DAAs zur Verwendung in der Behandlung von HCV
ES2529143B1 (es) 2011-10-21 2015-10-26 Abbvie Inc. Combinación de al menos dos agentes antivirales de acción directa, ribavirina pero no interferón para uso de tratamiento del vhc
EA201890507A1 (ru) * 2013-03-14 2018-07-31 Эббви Инк. Комбинация противовирусных препаратов прямого действия и рибавирина для лечения пациентов с hcv

Also Published As

Publication number Publication date
ES2654109T3 (es) 2018-02-12
MX2015012536A (es) 2016-01-12
CN108187056A (zh) 2018-06-22
KR20180045055A (ko) 2018-05-03
CN109908353A (zh) 2019-06-21
PL2968302T3 (pl) 2018-04-30
IL240445B (en) 2019-07-31
SG10201709840UA (en) 2018-01-30
LT2968302T (lt) 2017-12-27
HUE036069T2 (hu) 2018-06-28
EP3318258A1 (en) 2018-05-09
PT2968302T (pt) 2018-01-03
TWI678205B (zh) 2019-12-01
ZA201705080B (en) 2019-02-27
SI2968302T1 (en) 2018-04-30
JP2019214585A (ja) 2019-12-19
SMT201800017T1 (it) 2018-03-08
HK1213191A1 (en) 2016-06-30
KR101853605B1 (ko) 2018-05-03
EP3733180A1 (en) 2020-11-04
AU2014239322A1 (en) 2015-08-27
EP3318258B1 (en) 2020-05-13
JP2016513703A (ja) 2016-05-16
EP3915559A1 (en) 2021-12-01
AU2014239322B2 (en) 2018-04-05
EA030482B1 (ru) 2018-08-31
PL2968302T4 (pl) 2018-04-30
AU2020201656A1 (en) 2020-03-26
JP6563894B2 (ja) 2019-08-21
CY1121474T1 (el) 2020-05-29
CN105007921A (zh) 2015-10-28
WO2014152635A9 (en) 2014-12-11
EA201890507A1 (ru) 2018-07-31
IL267927A (en) 2019-09-26
SG11201507361YA (en) 2015-10-29
KR20150129035A (ko) 2015-11-18
CA2901818A1 (en) 2014-09-25
AU2018202581B2 (en) 2019-12-05
CN105007921B (zh) 2018-12-11
CA2901818C (en) 2021-05-04
EA201591701A1 (ru) 2016-02-29
IL240445A0 (en) 2015-09-24
US20140274934A1 (en) 2014-09-18
TW201505633A (zh) 2015-02-16
JP2019167347A (ja) 2019-10-03
DK2968302T3 (en) 2017-12-18
BR112015020918A2 (pt) 2017-07-18
EP2968302B1 (en) 2017-09-06
AU2018202581A1 (en) 2018-05-10
TW202002979A (zh) 2020-01-16
WO2014152635A1 (en) 2014-09-25
HRP20171898T1 (hr) 2018-04-06
RS56735B1 (sr) 2018-03-30
EP2968302B9 (en) 2019-02-13
NO3090119T3 (enExample) 2018-03-31
EP2968302A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
EP2968301B1 (en) Combination of two antivirals for treating hepatitis c
AU2018202581B2 (en) Combination of direct acting antiviral agents and ribavirin for treating HCV patients
AU2015240754B2 (en) Methods for treating HCV
AU2020202560A1 (en) Methods for treating HCV
US20220288153A1 (en) Methods for Treating HCV
HK40037284A (en) Combination of direct acting antiviral agents and ribavirin for treating hcv patients
HK1244668B (en) Combination of two antivirals for treating hepatitis c
HK1213191B (en) Combination of direct acting antiviral agents and ribavirin for treating hcv patients
HK1223817B (en) Combination of two antivirals for treating hepatitis c